Skip to main content
. Author manuscript; available in PMC: 2014 May 1.
Published in final edited form as: Antiviral Res. 2013 Mar 21;98(2):135–143. doi: 10.1016/j.antiviral.2013.03.009

Figure 3. Effect of post-exposure vaccination with MP-12 or MP-12 lacking NSs on survival outcome in mice challenged by i.n route with wt RVFV.

Figure 3

Mice (n=7–10) in each group were challenged with 103.3 PFU of RVFV then treated s.c. with placebo (20 min post-exposure), or 105 PFU of MP-12, rMP12-C13type, or rMP12-mPKRN167 at A) 20 min, B) 6 h, or C) 24 h post-exposure. *P < 0.05, **P < 0.01 compared to placebo-treated animals; aP < 0.05, bP < 0.01 compared to MP-12-treated animals.